G3.0 (15mg)
Technical Specifications
| Purity (HPLC) | ≥97% (HPLC) |
| CAS Number | 2381089-83-2 |
G3.0 (15mg)
| Purity (HPLC) | ≥97% (HPLC) |
| CAS Number | 2381089-83-2 |
| Form | White lyophilized powder |
| Storage | -20°C |
| Sequence | Modified triple incretin agonist |
| Molecular Weight | 4,803.56 g/mol |
| Salt Form | Acetate |
| Solubility | Soluble in aqueous buffer |
EUR list price · HU, SK, CZ, PL
Same EUR list price for delivery to Hungary, Slovakia, Czech Republic, and Poland. Checkout is charged in EUR.
Indicative HUF / CZK / PLN amounts are converted from EUR for reference only; Slovakia uses EUR. Rates are approximate. Checkout in EUR.
Triple GLP-1 / GIP / Glucagon receptor agonist for advanced metabolic research. 15mg vial, ≥99% HPLC purity.
Strictly for Laboratory Research Use Only.
Not for human consumption, veterinary use, or diagnostic purposes.
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Origin: Triple GIP/GLP-1/glucagon receptor agonist by Eli Lilly
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
2-8°C
G3.0 (15mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Synthesized for strict analytical consistency. Verified via HPLC/MS.View Quality Standards →